Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Neuroblastoma: a neurochemical approach.

Schor NF.

J Child Neurol. 1991 Jul;6(3):220-8. Review.

PMID:
1651966
2.

Aiming at neuroblastoma and hitting other worthy targets.

Schor NF.

J Child Neurol. 2013 Jun;28(6):768-73. doi: 10.1177/0883073813483173. Epub 2013 Apr 10. Review.

PMID:
23576410
3.

Targeting oncogene expression in a childhood cancer.

Tuthill MC, Wada RK.

Hawaii Med J. 2003 Oct;62(10):224-5. Review. No abstract available.

PMID:
14631595
4.

Neuroblastoma as a neurobiological disease.

Schor NF.

J Neurooncol. 1999 Jan;41(2):159-66. Review.

PMID:
10222436
5.

Neuroblastoma: biology and therapy.

Matthay KK.

Oncology (Williston Park). 1997 Dec;11(12):1857-66; discussion 1869-72, 1875. Review.

6.

Treatment of neuroblastoma in patients with neurocristopathy syndromes.

Nemecek ER, Sawin RW, Park J.

J Pediatr Hematol Oncol. 2003 Feb;25(2):159-62. Review.

PMID:
12571470
7.

The potential of amifostine: from cytoprotectant to therapeutic agent.

Santini V, Giles FJ.

Haematologica. 1999 Nov;84(11):1035-42. Review.

8.

Human neuroblastoma: from basic science to clinical debut of cellular oncogenes.

Schwab M.

Naturwissenschaften. 1999 Feb;86(2):71-8. Review.

PMID:
10084150
9.

New approaches to pharmacotherapy of tumors of the nervous system during childhood and adolescence.

Schor NF.

Pharmacol Ther. 2009 Apr;122(1):44-55. doi: 10.1016/j.pharmthera.2009.01.001. Epub 2009 Jan 23. Review.

10.

A role for distinct cell types in determining malignancy in human neuroblastoma cell lines and tumors.

Ross RA, Biedler JL, Spengler BA.

Cancer Lett. 2003 Jul 18;197(1-2):35-9. Review.

PMID:
12880957
11.

Rapid COJEC versus standard induction therapies for high-risk neuroblastoma.

Peinemann F, Tushabe DA, van Dalen EC, Berthold F.

Cochrane Database Syst Rev. 2015 May 19;(5):CD010774. doi: 10.1002/14651858.CD010774.pub2. Review.

PMID:
25989478
12.

Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).

Kurbacher CM, Mallmann PK.

Anticancer Res. 1998 May-Jun;18(3C):2203-10. Review.

PMID:
9703784
13.
14.

Genome and transcriptome analysis of neuroblastoma advanced diagnosis from innovative therapies.

Coco S, Tonini GP, Stigliani S, Scaruffi P.

Curr Pharm Des. 2009;15(4):448-55. Review.

PMID:
19199972
15.

The NGF story and neuroblastoma.

Nakagawara A.

Med Pediatr Oncol. 1998 Aug;31(2):113-5. Review.

PMID:
9680939
16.

Origin of neuroblastic tumors: clues for future therapeutics.

Mora J, Gerald WL.

Expert Rev Mol Diagn. 2004 May;4(3):293-302. Review.

PMID:
15137897
17.

Retinoids in pediatric onco-hematology: the model of acute promyelocytic leukemia and neuroblastoma.

Masetti R, Biagi C, Zama D, Vendemini F, Martoni A, Morello W, Gasperini P, Pession A.

Adv Ther. 2012 Sep;29(9):747-62. doi: 10.1007/s12325-012-0047-3. Epub 2012 Aug 28. Review.

PMID:
22941525
18.
19.

Intensive chemotherapy with stem cell support-experience in pediatric solid tumours.

Pinkerton CR.

Bull Cancer. 1995;82 Suppl 1:61s-65s. Review.

PMID:
7626856
20.

Neuropeptide Y in neural crest-derived tumors: effect on growth and vascularization.

Kitlinska J.

Cancer Lett. 2007 Jan 8;245(1-2):293-302. Epub 2006 Mar 2. Review.

PMID:
16513255

Supplemental Content

Support Center